As more evidence mounts in favour of the involvement of IDO in the TME of HNSCC and a better understanding of its mechanistic role in HNSCC immune modulation emerges, IDO‐based therapies are likely to be translated to clinical practice to improve outcomes for HNSCC patients. Here, IDO1 is linked to head and neck squamous cell carcinoma.